Mad Money 06/03/26 | Audio Only

Key Concepts

• Market Supply/Demand Imbalance: The risk that an excess of new IPOs and secondary offerings will overwhelm investor demand, leading to market declines.
• AI Infrastructure Buildout: The massive capital expenditure required for data centers, compute power, and energy, driving the need for companies to raise equity.
• Market Donor: A term used to describe a high-performing stock (specifically Nvidia) that investors sell to raise cash to participate in new, high-profile IPOs.
• Pro-Forma Financials: Financial statements that adjust for recent acquisitions to provide a more accurate picture of a company's current state.
• Market Orders vs. Limit Orders: The danger of using "market orders" (buying at any price) during volatile IPO openings versus "limit orders" (setting a maximum price).
• GLP-1 Agonists: A class of drugs (e.g., Zepbound, Wegovy) used for diabetes and weight loss, representing a major revenue driver for pharmaceutical companies like Eli Lilly.

---

1. Market Outlook and the "Supply" Problem

Jim Cramer argues that the current bull market is threatened not by interest rates or geopolitics, but by an excess of new supply. With major players like Anthropic, SpaceX, and potentially OpenAI planning IPOs, alongside secondary offerings from tech giants like Alphabet, Microsoft, and Amazon, the market faces a liquidity crunch.

• The "Foot Race": Companies are in a race to raise capital to fund the $600 billion+ required for the next phase of AI data center infrastructure.
• The "Market Donor" Effect: Cramer warns that investors are selling winners—specifically Nvidia—to fund participation in these new IPOs. While he remains a long-term believer in Nvidia, he expects volatility as it acts as a "piggy bank" for the market.

2. Deep Dive: Eli Lilly (LLY)

Cramer highlights Eli Lilly as a defensive, high-growth play insulated from broader economic volatility.

• Catalysts:
  • Retatrutide: A "triple-hormone" agonist (GLP-3) showing weight loss results comparable to bariatric surgery.
  • Verve-102: Early-stage gene therapy for high cholesterol showing a 62% reduction in LDL with a single infusion.
  • Strategic Acquisitions: Recent purchases of vaccine makers (Curvo, Limit Biologics) to diversify beyond GLP-1s.
  • PBM Coverage: New agreements with CVS Caremark and Medicare Part D programs significantly expand patient access to Zepbound and Mounjaro.
• Financials: Revenue grew from $24.5B (2020) to $65.2B (2023), with a 25% CAGR in earnings.

3. IPO Analysis: Applied Aerospace and Defense (ADX)

Cramer analyzes the recent IPO of Applied Aerospace, a contract manufacturer for the military-industrial complex.

• Business Model: An outsource manufacturer for mission-critical subsystems in extreme environments.
• Financial Complexity: The company is a private-equity-backed "rollup" (nine acquisitions since 2021). While GAAP earnings show losses, Cramer suggests using EBITDA to evaluate the company.
• Valuation: With an enterprise multiple of ~31, Cramer views the stock as slightly expensive but a "story he wants to own" if it pulls back to the mid-teens.

4. Corporate Spotlight: Prologis (PLD)

CEO Dan Letter discussed the company’s pivot from pure logistics to AI infrastructure.

• Data Center Strategy: Prologis has energized 5.6 gigawatts of power across its land bank, positioning itself as a critical landlord for AI data centers.
• Core Business: The company remains "sold out" of large-format logistics space, with e-commerce driving a 3x higher demand for warehouse space compared to brick-and-mortar.

5. The SpaceX IPO Warning

Cramer expresses deep concern regarding the upcoming SpaceX IPO, specifically the risk to retail investors.

• The Risk: Retail investors using "market orders" at the open may be "gafted" (crushed) if the stock opens at double its $135 offering price.
• Recommendations:
  • Book runners should ban market orders on the first day.
  • Regulators/brokers should allow for "ready sellers" (unlocking some insider shares) to prevent the stock from soaring to unsustainable levels (e.g., a $4 trillion valuation).

6. Lightning Round Insights

• Take-Two Interactive (TTWO): A "great idea" due to the upcoming GTA 6 release, but buy incrementally due to volatility.
• DoorDash (DASH): A strong company, but the current 32x earnings multiple may be too high; a better entry point would be $100–$120.
• Axon Enterprise (AXON): Hold; the product is excellent, but the high P/E multiple is causing current selling pressure.
• Boeing (BA): Avoid; the stock is currently trading as a proxy for geopolitical risk/war.
• Becton Dickinson (BDX): A buy; Cramer notes it is trading at an historically inexpensive valuation.

---

Synthesis

The market is currently in a "battlefield" phase characterized by a massive capital-raising cycle for AI infrastructure. Cramer’s core advice is to prioritize companies with strong, proven revenue streams (like Eli Lilly) while exercising extreme caution with new, high-hype IPOs. He emphasizes that while the AI revolution is the "fourth industrial revolution," the short-term supply of new stock will likely create a difficult environment for shareholders, necessitating patience and the use of limit orders rather than market orders.